Home
About Us
AdAlta at a glance
Board
Management Team
World Class Scientific Advisors
Technology
i-bodies
The i-body platform
Scientific Publications
Pipeline
The Growing AdAlta Pipeline
Fibrosis
CAR-T cancer therapeutics
Investors
Annual and Financial Reports
Presentations
Analyst Reports
ASX Announcements
News & Media
Corporate Governance
Contact Us
Nothing Found
Sorry, but nothing matched your search terms. Please try again with some different keywords.
Search for:
Archives
2016 News
Initial Director’s Interest Notice
AdAlta Extends Board with Appointment of US-Based Non Executive Director
Director Appointment
Results of AdAlta AGM 2016
AGM Presentation
2015 News
AdAlta and The University of Melbourne to develop i-bodies for the treatment of various eye diseases
Japanese patent granted for AdAlta i-body technology
AdAlta appoints Dr Paul MacLeman Chairman
AdAlta expands its scientific advisory team
2014 News
AdAlta expands its scientific advisory team
Lonza and AdAlta Announce a Strain Development Contract for Novel Biologic Therapeutics
2013 News
AdAlta collaborates with Crossbeta to find i-body for Alzheimer’s disease
AdAlta awarded voucher to explore benefits of technologies with Ferring Research Institute
2012 News
AdAlta and Baker IDI sign agreement to identify i-bodies to anti-thrombotic target
AdAlta and Roche sign agreement to evaluate shark antibody technology
2011 News
US patent granted for AdAlta i-body technology
AdAlta receives VC investment from Perth-based Yuuwa Capital